Y-mAbs Shares Halted on Day of FDA Advisory Panel Meeting
October 28 2022 - 3:09PM
Dow Jones News
By Josh Beckerman
Y-mAbs Therapeutics Inc. shares were halted Friday morning as a
Food and Drug Administration advisory committee was scheduled to
review the company's drug application.
The Oncologic Drugs Advisory Committee was scheduled to discuss
Omblastys, or omburtamab.
In one of the documents that the FDA posted in advance of the
meeting, the agency noted "uncertainty" related to a clinical trial
and said it is requesting "discussion regarding the assessment of
efficacy."
Y-mAbs shares fell 27% Wednesday and 20% Thursday. Before the
halt Friday, they were up 1% at $8.93.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 28, 2022 14:54 ET (18:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024
